The psychotropic effects of Psilocybe mushrooms were largely unknown in the West until the 1950s, despite evidence that they had a long history of indigenous use in Central and South America, and possibly other parts of the world.
Western civilisations had very little knowledge of this relatively ‘new‘ psychotropic and subsequently banned research into its effects shortly after its discovery. Little or no published human research into psilocybin was conducted between 1970 and 1990. In the 1990s, research began again slowly due to the work of some determined scientists such as Rick Strassman, David Nichols and Charles Grob.
Now, psilocybin is being researched as a tool for tacking depression, OCD, addiction, end of life anxiety and a number of other indications. As phase 2 trials launch around the world, psilocybin is looking to be an increasingly important substance for psychotherapy.
About these modules
These slides were made in collaboration with Mind Medicine Australia, who are seeking to establish safe and effective psychedelic-assisted treatments for mental illness in Australia.
These slides are primarily for use in medical education settings but have been carefully designed to ensure that they are accessible for a wide range of people. They will therefore provide a rapid overview for medical students and other healthcare professionals. They are free to use; the aim of both organisations is to optimise dissemination of research into practice, so if these slides are of use to you, please use them.